1
Clinical Trials associated with gp140 DP vaccine(Janssen Vaccines & Prevention)A Phase 1/2a Trial to Evaluate the Safety/Tolerability and Immunogenicity of Homologous Ad26 Mosaic Vector Regimens or Ad26 Mosaic and MVA Mosaic Heterologous Vector Regimens, With High-Dose, Low-Dose or no Clade C gp140 Protein Plus Adjuvant for HIV Prevention
The purpose of this study is to assess the safety and tolerability of various regimens containing adenovirus serotype 26-Mosaic -Human Immunodeficiency Virus (Ad26.Mos.HIV), Modified Vaccinia Ankara (MVA)-Mosaic, and/or HIV type 1 Clade C glycoprotein 140 drug product (gp140 DP) components and to compare envelope binding antibody responses between the different vaccine regimens.
100 Clinical Results associated with gp140 DP vaccine(Janssen Vaccines & Prevention)
100 Translational Medicine associated with gp140 DP vaccine(Janssen Vaccines & Prevention)
100 Patents (Medical) associated with gp140 DP vaccine(Janssen Vaccines & Prevention)
100 Deals associated with gp140 DP vaccine(Janssen Vaccines & Prevention)